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ABSTRACT  
Rationale: N-acetylcysteine (NAC) is currently under investigation as an adjunctive 
treatment for schizophrenia. The therapeutic potential of NAC may involve modulation of 
brain glutamate function, but its effects on brain glutamate levels in schizophrenia have not 
been evaluated.  
Objectives: The aim of this study was to examine whether a single dose of NAC can alter 
brain glutamate levels. A secondary aim was to characterise its effects on regional brain 
perfusion. 
Methods: In a double-blind placebo-controlled crossover study, nineteen patients with a 
diagnosis of schizophrenia underwent two MRI scans, following oral administration of 
2400mg NAC or matching placebo. Proton magnetic resonance spectroscopy was used to 
investigate the effect of NAC on glutamate and Glx (glutamate plus glutamine) levels scaled 
to creatine (Cr) in the anterior cingulate cortex (ACC) and in the right caudate nucleus. 
Pulsed continuous arterial spin labeling was used to assess the effects of NAC on resting 
cerebral blood flow (CBF) in the same regions.   
Results: Relative to the placebo condition, the NAC condition was associated with lower 
levels of Glx/Cr, in the ACC (P < 0.05), but not in the caudate nucleus. There were no 
significant differences in CBF in the NAC compared to placebo condition.  
Conclusions: These data provide preliminary evidence that NAC can modulate ACC 
glutamate in patients with schizophrenia. In contrast, physiological effects of NAC on the 
brain were not detectable as between session changes in rCBF. Future studies assessing the 
effects of a course of treatment with NAC on glutamate metabolites in schizophrenia are 
indicated.   
 
 
Keywords: Schizophrenia, glutamate, n-acetylcysteine, magnetic resonance spectroscopy, 
arterial spin labelling, anterior cingulate cortex. 
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INTRODUCTION  
Approximately two thirds of patients with schizophrenia show a suboptimal symptomatic 
response to standard antipsychotic administration (Meltzer 1997; Lindenmayer 2000). There 
are substantial on-going efforts to develop alternative pharmacological interventions for this 
group, with a major focus on compounds that can modulate glutamatergic neurotransmission 
(Buchanan et al. 2007; Kinon and Gómez 2013; Bugarski-Kirola et al. 2016, 2017). The 
ability of such compounds to modulate glutamate levels can be tested in animal models 
during early stages of drug development (Moghaddam and Krystal 2012), but it is not known 
whether similar effects occur in patients with schizophrenia. This lack of studies evaluating 
target engagement in man is a major limiting factor in glutamatergic drug development for 
schizophrenia (Javitt et al. 2018).  
 
N-Methyl-D-Aspartate (NMDA) receptor antagonists, such as phencyclidine or ketamine, 
produce effects that resemble the symptoms of schizophrenia in man (Javitt and Zukin 1991; 
Krystal et al. 1994)  and increase glutamate metabolite levels in frontal cortical brain areas 
(Moghaddam et al. 1997; Rowland 2005; Stone et al. 2012; Javitt et al. 2018). On this basis, 
glutamatergic theories of schizophrenia predict an elevation in cortical glutamate, and 
accordingly a therapeutic potential for compounds that can facilitate NMDA function and 
decrease glutamate release (Moghaddam and Javitt 2012).  
 
Brain glutamate concentrations can be measured in man using localised proton magnetic 
resonance spectroscopy (1H-MRS). This approach estimates concentrations of glutamate 
(Glu), its metabolite glutamine (Gln), and the combined measure of glutamate plus glutamine 
(Glx) in a pre-specified region of interest. 1H-MRS studies in people with schizophrenia or 
psychosis compared to healthy volunteers have reported both increases and decreases in 
regional glutamate levels, which may reflect illness stage, medication effects or other 
methodological factors (Merritt et al. 2016). Recent studies indicate that glutamate levels in 
the anterior cingulate cortex (ACC) or striatum may be particularly elevated in patients who 
remain unwell after conventional antipsychotic treatment, compared to patients who have 
responded well (Egerton et al. 2012; Demjaha et al. 2014; Goldstein et al. 2015; 
Mouchlianitis et al. 2016). These findings may suggest that in patients who remain unwell 
despite antipsychotic treatment, elevated glutamatergic concentration in tissue is not reduced 
by conventional antipsychotic medication (Egerton et al. 2017), and that adjunctive 
interventions that can reduce glutamate levels may benefit this group. Evaluation of the 
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ability of a glutamatergic compound to reduce 1H-MRS glutamate levels in schizophrenia 
may therefore provide a biomarker of target engagement, which could be used to facilitate 
clinical trials. 
   
One compound which is currently under investigation for this purpose is N-acetylcysteine 
(NAC), which can decrease neuronal glutamate release (Anwyl 1999). In rats, PCP-
stimulated increases in frontal glutamate are blocked by NAC pre-treatment (Baker et al. 
2002), which could indicate its potential for use as an antipsychotic drug. NAC is a precursor 
to the amino acid L-cysteine (Arakawa and Ito 2007) and its oxidised form L-cystine, which 
is thought to modulate extracellular glutamate levels through interaction with the 
cystine/glutamate antiporter, System xc
-  (Bridges et al. 2012a). System xc
- exchanges 
extracellular L-cystine with intracellular L-glutamate, most notably across the membrane of 
glial cells (Bridges et al. 2012b). Glutamate transported into the extracellular space through 
System xc
- activates extrasynaptic mGluR2/3 receptors (Baker et al. 2002; Xi et al. 2003; 
Mohan et al. 2011), to decrease neuronal glutamate release (Anwyl 1999). Accordingly, 
NAC’s ability to attenuate phencyclidine-stimulated glutamate increases appears to be 
mediated by a mGluR2/3-mediated mechanism (Baker et al. 2002). The effects of NAC on 
1H-MRS measures of glutamate in people with schizophrenia have not been reported. 
However, in cocaine-dependent individuals, single dose NAC administration decreases ACC 
1H-MRS glutamate levels (Schmaal et al. 2012). This raises the possibility that NAC may 
also be able to decrease glutamate levels in patients with schizophrenia.   
 
Another potential biomarker for antipsychotic efficacy may be drug-induced changes in 
regional brain activity, as measured through changes in resting regional cerebral blood flow 
(rCBF) due to the phenomenon of neuro-vascular coupling (Allen et al. 2016). Changes in 
rCBF have been observed after administration of single doses of antipsychotic compounds in 
both people with schizophrenia and in healthy volunteers (Lahti et al. 2003; Fernández-Seara 
et al. 2011; Handley et al. 2013; Shcherbinin et al. 2015). These studies have shown increases 
in CBF occurring in regions associated with the mechanism of action of the drug and relevant 
to schizophrenia, including the striatum, thalamus and ACC (Goozée et al. 2014). Arterial 
spin labelling (ASL) provides a modern MRI approach to measure rCBF, and is well-suited 
to examining the changes in brain activity arising after administration of single oral doses of 
centrally-acting compounds (Handley et al. 2013; Shcherbinin et al. 2015; Pollak et al. 2015). 
Changes in rCBF following NAC administration in regions previously associated with 
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schizophrenia pathophysiology (Goozée et al. 2014) or with antipsychotic response (Tost et 
al. 2010; Handley et al. 2013) could therefore also indicate therapeutic potential.   
 
The primary aim of the current study was to determine whether a single dose of NAC 
compared to placebo decreases brain glutamate metabolites in schizophrenia. Using 1H-MRS, 
we evaluated glutamate levels in the ACC and right caudate nucleus, the brain areas where an 
elevation in glutamate has been linked to a poor antipsychotic response (Egerton et al. 2012; 
Demjaha et al. 2014; Goldstein et al. 2015; Mouchlianitis et al. 2016), and where, in 
preclinical studies, the administration of NAC reduces glutamate levels (Baker et al. 2008; 
Durieux et al. 2015). The secondary aim was to use ASL to characterise the effects of NAC 
on rCBF in these regions, and to investigate whether these alterations are correlated with 
NAC-induced changes in glutamate metabolites.  
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METHODS  
Participants and clinical measures 
This study received ethical approval from the NRES London - Harrow NHS ethics committee 
and was registered on clinicaltrials.gov, study number NCT02483130.    
 
Twenty participants meeting DSM-IV criteria for schizophrenia were recruited from 
outpatient services within the South London and the Maudsley NHS Foundation Trust. Data 
from previous studies (Egerton et al. 2012; Demjaha et al. 2014) indicated that a sample size 
of 18 would be required to detect a 15% within-subject difference in ACC glutamate at 80% 
power and an alpha = 0.05, while a sample of 12 in each group provides 80% power to detect 
a 5% within-group difference in rCBF (Murphy et al. 2011; Handley et al. 2013). 
 
Inclusion required written informed consent and good physical health, as determined by a 
physical health screen. Exclusion criteria included contraindications to MRI at 3 Tesla or 
contraindications to NAC administration, including pregnancy, history of asthma, seizure, 
and drug or alcohol dependency. The study excluded patients with current or previous NAC 
or clozapine use. Symptom severity was assessed during the health screen using the Positive 
and Negative Syndrome Scale (PANSS; (Kay and Qpjer 1982)), Clinical Global Impression-
Severity (CGI-S; (Guy, 1976)), and functioning was assessed using Global Assessment of 
Functioning scale (GAF; (Hall 1995)).  
 
Administration of N-acetylcysteine and placebo  
The dose of NAC, and the time period between NAC administration and MRI scanning 
followed the previous study of Schmaal et al (2012), which detected decreases in 
glutamatergic measures one hour following 2400mg NAC administration in cocaine-
dependent individuals, as peak plasma levels of NAC occur 1 – 2 hours after oral 
administration (Holdiness, 1991). This single dose is also similar to that used in repeated 
administration in clinical trials of NAC in schizophrenia (Berk et al. 2008; Farokhnia et al. 
2013; Conus et al. 2018). The order of NAC and placebo administration was block 
randomised such that an equal number of participants received either NAC or placebo in the 
first visit. MRI sessions were performed exactly seven days apart and at the same time of day. 
The local pharmacy distributed blinded medication packs with visually identical appearing 
capsules for each session. Both the research team and the participants were blind to the order 
and nature of each administration.  
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Magnetic Resonance Imaging 
MRI data were acquired on a 3 Tesla MR750 scanner (General Electric, Chicago, USA). The 
scanning session commenced with a localizer, standard Axial T2-weighted fast spin echo 
scan (TR / TE= 4380 / 55.72) and a T1-weighted structural scan (TR / TE = 7.312 / 3.01). 
The T1-weighted acquisition was used to plan 1H-MRS voxel placement, and for calculation 
of 1H-MRS voxel tissue content. 1H-MRS spectra were acquired in 8 cm3 (2 x 2 x 2 cm3) 
voxels prescribed in the bilateral ACC and right caudate nucleus (Figure 1). Spectra were 
acquired using a conventional PRESS (Point RESolved Spectroscopy) acquisition with 96 
averages, TR = 3000 ms and with a TE = 30 ms in the ACC (Egerton et al. 2012) and a TE = 
35 ms in the caudate (De la Fuente-Sandoval et al. 2011). An additional 16 averages were 
acquired without water suppression for subsequent eddy current correction and water scaling. 
The acquisition used the standard GE PROBE (PROton Brain Examination) sequence with 
CHESS (CHEmically Selective Suppression) water suppression. For measurement of regional 
CBF, a 3D pseudo-continuous ASL (pCASL) acquisition was used. Arterial blood was 
labeled using a long (1.5s) train of adiabatic radio frequency pulses. After a post-labelling 
delay of 1.5s, perfusion images were acquired with a 3D Fast Spin Echo (FSE) stack-of-
spirals multi-shot readout (TE/TR = 32 ms / 5500 ms; ETL= 64) (Dai et al. 2008; Handley et 
al. 2013). CBF maps were computed in physiological units of ml blood per 100mg of tissue 
per minute, with a voxel size of 1 x 1 x 3 mm3.  
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Figure 1. 1H-MRS voxel positioning and example spectra in the anterior cingulate cortex (A) 
and right caudate nucleus (B).  
 
Image processing  
1H-MRS spectra were analysed with LCModel version 6.3-0I (Provencher, 1993) using the 
standard basis set of 16 metabolites (L-alanine, aspartate, creatine, phosphocreatine, GABA, 
glucose, glutamine, glutamate, glycerophosphocholine, glycine, myo-inositol, L-lactate, N-
acetylaspartate, N-acetylaspartylglutamate, phosphocholine, taurine) provided with 
LCModel, for the same field strength, PRESS sequence and echo times. Spectral quality was 
determined by visual inspection, as well as through values for spectral line-width, signal to 
noise ratio and the Cramér Rao Lower Bounds of the individual metabolite estimates. To 
calculate 1H-MRS voxel tissue content, the T1-weighted structural images were segmented 
into grey matter, white matter and cerebrospinal fluid (CSF) using Statistical Parametric 
Mapping 8 (SPM-8) (http//www.fil.ion.ucl.ac.uk/spm) running in Matlab 6.5 (Mathworks 
Inc. Sherbon MA, USA). GE Sage 7 (GE Medical Systems) was used to locate the 
coordinates of each voxel, which was then mapped on to the segmented structural image 
using in-house software. For consistency with the study of Schmaal et al (2012), glutamate 
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and Glx signals referenced to creatine were used for the primary statistical analyses, and we 
also report water-scaled metabolite levels corrected for voxel tissue content. Metabolite 
values were corrected for voxel tissue content using the formula: Mcorr = M*(wm + 1.21*gm 
+ 1.55* CSF) / (wm + gm), where M is the uncorrected metabolite, and wm, gm and CSF 
indicate the fraction of white and grey matter and cerebrospinal fluid content in the voxel. 
The formula assumes a CSF water concentration of 55,556mol/m3 with the LCModel default 
brain water concentration of 35,880 mol/m3 (Kreis et al. 1993; Gasparovic et al. 2006).  
 
Computation of the CBF values was done in the scanner following the methodology outlined 
in the recent ASL consensus paper (Alsop et al. 2015).  Individual CBF maps were then 
transformed to the reference space of the Montreal Neurological Institute (MNI) using the 
Automatic Software for ASL Processing (ASAP) toolbox (Mato Abad et al. 2016) running in 
SPM-8 under Matlab 6.5. Default pre-processing options were used for skull-stripping, co-
registration to the subject’s 3D anatomical scan, and normalisation to the MNI template based 
on unified segmentation.  The normalised maps were finally smoothed using an 8 mm kernel. 
 
Statistical analysis 
The effects of NAC on 1H-MRS metabolite levels were determined using paired samples t-
tests in SPSS software (version 22.0, Chicago, Illinois). For Glu/Cr and Glx/Cr in each voxel, 
the threshold for statistical significance was defined as p < 0.05, and the effect size was 
calculated as Cohen’s d for significant values. The effects of NAC on rCBF were determined 
using within-subjects, second-level analysis implemented in SPM-8. For rCBF region of 
interest (RoI) analysis, ACC and caudate masks were created using the Talairach Daemon 
database atlas implemented in SPM (Lancaster et al. 1997, 2000). Spearman’s correlation 
coefficients were used to explore relationships between the absolute change (NAC minus 
placebo) in Glu/Cr, Glx/Cr and the absolute change in rCBF in the ACC or caudate nucleus.  
 
Finally, to explore potential effects of NAC on regional CBF we conducted a whole brain 
voxel-wise search at P < 0.001 uncorrected for multiple comparisons, then used cluster-based 
FDR correction for statistically significant clusters accepted at P < 0.05.  
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RESULTS  
Sample characteristics 
Participant demographic and clinical measures are presented in Table 1. MRI datasets were 
available in 19 of the 20 included participants as one patient experienced nausea and 
vomiting one hour after NAC administration and did not complete the scanning session. The 
remaining 19 participants reported no adverse effects after either NAC or placebo 
administration. Of the nineteen included participants, seven participants were currently 
receiving olanzapine, four risperidone, two aripiprazole, two paliperidone, one haloperidol, 
one zuclopenthixol, one flupentixol, and one was currently not taking any antipsychotic 
medication. Participants were receiving antipsychotic medication from four months to 19 
years (mean (SD) months = 83.69 (71.30)), and had an illness duration of four months to 30 
years (mean (SD) months = 152.00 (93.56) Eight participants were additionally receiving 
citalopram (2), procyclidine (2), olanzapine (1), venlafaxine (1), propanol (1), and sodium 
valproate (1).  
 
Age, years  41.57 (10.87) 
Gender, Female/Male 3/17 
Education, years  13.89  (1.85) 
PANSS – Positive  12.72  (4.17) 
PANSS – Negative  13.72  (3.85) 
PANSS – General  23.11  (6.06) 
PANSS – Total  49.56  (12.27) 
CGI  3.00    (0.57) 
GAF  59.31  (4.79) 
Table 1. Subject Demographics and Clinical measures. Data are reported as mean (standard 
deviation). Abbreviations: CGI, Clinical Global Impression score; GAF, Global Assessment 
of Functioning score; PANSS, Positive and Negative Syndrome Scale scores. 
 
1H-MRS spectral quality 
Due to a scanner fault, one ACC dataset was not collected, leaving 18 1H-MRS datasets in the 
ACC and 19 1H-MRS datasets in the caudate nucleus available for analysis. For all reported 
metabolites, individual Cramér Rao Lower Bounds were below 20% and no spectra were 
excluded on the basis of poor quality. There were no significant differences in values relating 
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to 1H-MRS data quality or voxel tissue content in the placebo compared to NAC condition 
(Table 2).  
 
Spectral quality measures   
 Anterior Cingulate Cortex  
 Placebo  NAC Statistic 
Line-width 0.04  (0.01) 0.04   (0.01) t(17) = 1.51,  P = 0.14 
S/N 22.7  (5.40) 22.05 (3.90) t(17) = 0.61,  P = 0.54 
WM 0.15  (0.10) 0.15   (0.09) t(17) = 0.13,  P = 0.90 
GM 0.56  (0.10) 0.57   (0.12) t(17) = -0.32, P = 0.75 
CSF 0.29  (0.12) 0.28   (0.08) t(17) = 0.26,  P = 0.80 
 Right Caudate Nucleus  
 Placebo NAC  
Line-width 0.07   (0.01) 0.07   (0.01) t(18) = -0.56, P = 0.57 
S/N 22.72 (5.43) 22.05 (3.96) t(18) = 1.93,  P = 0.68 
WM 0.49   (0.09) 0.47   (0.06) t(18) = 0.81,  P = 0.43 
GM 0.48   (0.11) 0.51   (0.05) t(18) = -1.05, P = 0.31 
CSF 0.03   (0.03) 0.02   (0.02) t(18) = 0.93,  P = 0.37 
Cramér Rao Lower Bounds (%):   
 Anterior Cingulate Cortex  
 Placebo  NAC Statistic 
Glu 6.66   (2.02) 6.77   (1.51) t(17) = -0.19, P = 0.85 
Glx 6.50   (1.09) 7.44   (2.12) t(17) = -1.88, P = 0.77 
NAA 3.22   (0.42) 3.00   (0.76) t(17) = 1.07,  P = 0.29 
TCho 3.16   (0.51) 3.07   (0.62) t(17) = 0.55,  P = 0.58 
MI 5.27   (1.87) 5.00   (1.02) t(17) = 0.92,  P = 0.36 
Cr 2.88   (0.58) 2.77   (0.54) t(17) = 0.69,  P = 0.49 
 Right Caudate Nucleus  
 Placebo NAC Statistic 
Glu 8.05   (1.22) 8.21   (2.34) t(18) = -0.30, P = 0.76 
Glx 10.26 (2.30) 10.26 (5.26) t(18) = 0.00,  P = 1.0 
NAA 3.36   (0.68) 3.21   (0.91) t(18) = 5.90,  P = 0.56 
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TCho 3.47   (0.51) 3.47   (0.51) t(18) = 1.00,  P = 1.00 
MI 8.47   (1.98) 9.15   (3.28) t(18) = -1.58, P = 0.13 
Cr 3.00   (0.33) 3.00   (0.33) t(18) = 0.43,  P = 0.66 
Table 2. Estimates of linewidths (ppm), signal-to-noise ratios, Cramér Rao Lower Bounds, 
and voxel white matter, grey matter and cerebrospinal fluid fractions in the anterior cingulate 
cortex and right caudate nucleus in placebo and NAC conditions. Data are presented as mean 
(standard deviation). Abbreviations: Cr, Creatine; CSF, cerebral spinal fluid; Glu, Glutamate; 
GM, grey matter; Glx, Glutamate + Glutamine; NAA, N-acetyl aspartate; S/N, signal to 
noise; TCho, Total Choline; mI, myo-Inositol; WM, white matter. 
 
Effect of NAC on voxel glutamate levels 
Compared to the placebo condition, the NAC condition was associated with significantly 
lower levels of Glx/Cr in the ACC (t(17) = 2.40; P = .03, d = 0.64; Figure 2, Table 3). There 
were no significant effects of condition on Glu/Cr in the ACC, on Glx/Cr or Glu/Cr in the 
right caudate nucleus (Figure 2), or on any of the other metabolites quantifiable from the 1H-
MRS spectra in either region (Table 3).    
 
 
Figure 2. Glutamate and Glx (glutamate and glutamine) metabolite levels in the anterior 
cingulate cortex and right caudate nucleus, scaled to creatine. Data are presented as mean 
values, with standard deviation denoted by error bars. * indicates the significantly lower 
levels of Glx/Cr in the ACC in the NAC compared to placebo condition (p < .05). 
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Metabolite Placebo NAC Statistic 
Referenced to creatine 
 Anterior cingulate cortex  
Glu/Cr 1.29 (0.20)  1.22 (0.18)  t(17) = 1.30,   P = 0.21 
Glx/Cr 1.86 (0.43)  1.63 (0.30)  t(17) = 2.40,  P = 0.03* 
NAA/Cr 1.31 (0.11)  1.28 (0.13)  t(17) = 0.86,  P = 0.40 
TCho/Cr 0.26 (0.03)  0.25 (0.02)  t(17) = 0.34,  P = 0.74 
MI/Cr 0.72 (0.10)  0.74 (0.14)  t(17) = -0.81, P = 0.43 
 Right caudate nucleus  
Glu/Cr 1.20 (0.11)  1.19 (0.19)  t(18) = 0.20,  P = 0.85 
Glx/Cr 1.69 (0.29)  1.70 (0.37)  t(18) = -0.05, P = 0.96 
NAA/Cr 1.28 (0.16)  1.22 (0.11)  t(18) = 1.44,  P = 0.17 
TCho/Cr 0.26 (0.03)  0.26 (0.02)  t(18) = 1.31,  P = 0.21 
MI/Cr 0.51 (0.10)  0.49 (0.10)  t(18) = 0.89,  P = 0.38 
Corrected for voxel tissue content  
 Anterior cingulate cortex  
Glu 14.67 (2.67)  14.77 (2.67)  t(17) = -0.12, P = 0.90 
Glx 22.55 (6.33)  19.80 (4.13)  t(17) = 1.92,  P = 0.07 
NAA 14.96 (2.16)  15.47 (1.28)  t(17) = -0.87, P = 0.39 
TCho 2.94   (0.52)  3.12   (0.49)    t(17) = -1.30, P = 0.21 
MI 8.19   (1.53)  8.97   (1.84)    t(17) = -1.85, P = 0.82 
Cr 11.48 (1.64)  12.19 (1.13)  t(17) = -1.68, P = 0.11 
 Right Caudate Nucleus  
Glu 11.20 (1.47)  12.66 (6.04)  t(18) = -0.98, P = 0.33 
Glx 15.87 (3.24)  18.68 (12.00)  t(18) = -0.98, P = 0.34 
NAA 11.95 (1.75)  12.82 (5.26)  t(18) = -0.67, P = 0.51 
TCho 2.48   (0.39)  2.76   (1.31)  t(18) = -0.88, P = 0.45 
MI 4.73   (0.78)  5.13   (2.13)  t(18) = -0.77, P = 0.45 
Cr 9.43   (1.46) 10.62 (4.36) t(18) = -1.07, P = 0.30 
Table 3. Creatine and water referenced, CSF corrected metabolite values in the anterior 
cingulate cortex and right caudate nucleus. Data are presented as mean, standard deviation 
and t-test. Abbreviations: Cr, Creatine; Glu, Glutamate; Glx, Glutamate + Glutamine; mI, 
myo-Inositol; NAA, N-acetyl aspartate; TCho, Total Choline. 
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Regional cerebral blood flow 
There was no significant difference in rCBF in the ACC (mean (SD) placebo = 47.22 (8.81); 
NAC = 46.83 (7.29); t(18) = .349, P = .73) or in the right caudate nucleus (mean (SD) 
placebo = 37.51 (7.48); NAC = 37.77 (6.71); t(18) -.310, P = .76) in the NAC compared to 
placebo condition. Similarly, whole brain voxel-wise analysis found no significant 
differences in CBF between conditions. There was also no significant difference in global 
CBF between conditions (mean (SD) placebo = 39.64 (10.02); NAC = 40.03 (9.13); t(18) = -
.398, P = .70). 
 
Relationship between glutamate metabolites, rCBF, and PANSS 
There were no significant correlations between change in Glx/Cr, Glu/Cr and change in rCBF 
in either the ACC or caudate (all P > .6). There were also no significant correlations between 
PANSS total, positive and negative scores and the change in Glu/Cr and Glx/Cr (all P > .1), 
or Glu/Cr and Glx/Cr in the placebo and NAC conditions in the ACC or caudate (all P > .3). 
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DISCUSSION 
This study examined the effects of a single dose of N-acetylcysteine (NAC) on brain 
glutamate levels and resting perfusion in patients with schizophrenia. Glx/Cr in the anterior 
cingulate cortex (ACC) were significantly lower following administration of NAC compared 
to the placebo, but no further differences in the other glutamate metabolite measures in the 
ACC or in the caudate nucleus were apparent. The NAC compared to placebo condition was 
not associated with significant differences in cerebral blood flow (CBF).  
 
The lower levels of ACC Glx/Cr after NAC compared with placebo administration in patients 
with schizophrenia is broadly consistent with a previous report of lower ACC glutamate 
following a single dose of NAC in cocaine-dependent individuals (Schmaal et al. 2012). That 
study described significantly lower levels of glutamate (in both creatine-scaled and water-
referenced values), and a trend for lower levels of Glx after NAC administration in cocaine-
dependent subjects but not in healthy controls, while we detected lower levels of Glx/Cr in 
the NAC condition in patients with schizophrenia. Although these results are similar, the 
different populations in these studies likely show different underlying neuropathology or 
neurobiological changes resulting from previous medication or drug use, which may have 
influenced sensitivity to NAC. It is also possible that the difference we see in Glx/Cr could be 
related to changes in creatine. However, CSF-scaled Glx levels showed a similar trend for 
lower levels in the NAC condition (P = .07). Our results thus provide preliminary evidence 
that NAC may decrease ACC glutamate metabolites in schizophrenia, but that will require 
further confirmation and replication. In addition, future studies will need to determine the 
extent to which lower levels of glutamate metabolites following a single dose of a 
glutamatergic compound are indicative of efficacy in improving symptoms over longer-term 
administration.  
 
One methodological limitation of the 1H-MRS approach that we applied is that the glutamine 
signal cannot be reliably estimated. We were therefore unable to determine the relative 
contributions of glutamine and glutamate to the lower levels of Glx/Cr observed on NAC 
administration, although this would be possible in future studies using 1H-MRS optimized for 
detection of glutamate and glutamine. Furthermore, as our study did not include a baseline 
scan, we are unable to determine the relative effects of NAC and placebo administration on 
resting 1H-MRS metabolite levels or rCBF.  A more general limitation of 1H-MRS is that as 
the signal reflects the total amount of glutamate in the voxel, it is not possible to ascribe the 
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effects we observed to changes in glutamate neurotransmission specifically. Previous 
research indicates that NAC increases extracellular glutamate, which is then thought to 
decrease neuronal glutamate release via activation of presynaptic mGluR2/3 receptors (Baker 
et al. 2002). Thus, changes in the 1H-MRS signal may reflect the net effect of both increases 
in extra-synaptic and decreases in intra-synaptic glutamate following NAC administration. 
Indeed, in non-human primates, a decrease in binding of the mGluR5 radiotracer [11C] 
ABP688 following NAC may reflect increases in extra-synaptic glutamate levels (Miyake et 
al. 2011; Sandiego et al. 2013).  
 
An additional limitation of our study is that the precise mechanism by which NAC may 
modulate the 1H-MRS glutamate signal is unclear. NAC can reduce neuronal glutamate 
release (Anwyl 1999), and modulate glutamate through System xc
- and mGluR2/3 signalling 
(Baker et al. 2002; Bridges et al. 2012b). However, NAC increases glutathione (GSH) (Berk 
et al. 2013), which decreases nitrosative stress (a marker of glutamate dysfunction) through 
redox modulation, whilst reducing NMDA activity (Berk et al. 2013; Samuni et al. 2013). 
Therefore, GSH and NMDA modulation may contribute to the 1H-MRS glutamate signal 
after NAC administration.  
 
A recent meta-analysis of 1H-MRS studies in schizophrenia suggests that there is no overall 
elevation in glutamate or Glx levels in the ACC / medial frontal cortex, but an increase in 
caudate glutamate and Glx levels, when compared to healthy controls (Merritt et al. 2016). 
Further studies have shown that ACC and caudate glutamate metabolites may be particularly 
elevated in patients in whom antipsychotic medication is ineffective (Egerton et al. 2012, 
2017; Demjaha et al. 2014; Goldstein et al. 2015; Mouchlianitis et al. 2016).  
 
These observations raise the possibility that the effects of NAC might be more marked in 
patients who have not responded to conventional treatment and have elevated glutamate 
levels. The current sample was not selected on the basis of antipsychotic response and had 
relatively low PANSS scores, which may therefore have limited the potential to observe a 
reduction in glutamate on NAC administration. Future studies could compare the effects of 
NAC or other glutamatergic interventions on glutamate levels in good versus poor 
antipsychotic responders.  
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Our second finding was that the NAC compared to placebo condition was not associated with 
significant differences in resting state perfusion in either the ACC or in the caudate, or in any 
other brain region. Previous studies that have used the same perfusion imaging approach have 
detected changes in regional perfusion after administration of single doses of several centrally 
acting compounds, including aripiprazole, haloperidol (Handley et al. 2013), risperidone 
(Shcherbinin et al. 2015), ketamine (Pollak et al. 2015), psilocybin (Carhart-Harris et al. 
2012) and fentanyl (Zelaya et al. 2012). However, these studies involved comparison of data 
from drug and placebo sessions conducted on the same day, and studies where subjects were 
scanned on separate days have not found significant effects of lamotrigine or ketamine 
(Murphy et al. 2011; Shcherbinin et al. 2015). Assessment over two separate days may 
therefore have contributed to the absence of an observable effect of NAC on regional 
perfusion in our study. At similar doses and time periods after administration, NAC can 
reduce brain glutamate in cocaine-dependent patients (Schmaal et al. 2012) and reduce 
frequency-deviant mismatch negativity amplitude and increase P300 amplitude in healthy 
volunteers (Gunduz-Bruce et al. 2012). In addition, differences in brain network connectivity 
are observed after 4 days of administration of 2400mg NAC during tobacco smoking 
abstinence (Froeliger et al. 2015). It thus seems unlikely that the lack of difference in 
perfusion following NAC reflects the sub-threshold doses or plasma levels. Nonetheless, the 
lack of any correlation between the change in Glx, glutamate and rCBF indicates the 
difference in ACC Glx/Cr following NAC administration is not driven by a difference in 
CBF. Alternative approaches, such as examining the effects of NAC versus placebo on rCBF 
on the same day, or the effects of NAC on resting state brain network functional connectivity 
may better reveal effects on brain neurophysiology.  
  
Early clinical trials of adjunctive administration of NAC in schizophrenia suggest it may have 
therapeutic effects (Lavoie et al. 2008; Berk et al. 2008, 2011; Bulut et al. 2009; Farokhnia et 
al. 2013; Dean et al. 2015; Conus et al. 2018). Our data provide preliminary evidence that 
these effects may be related to changes in brain glutamate levels. However, our findings are 
based on a single dose of NAC, and 1H-MRS imaging studies of longer-term NAC 
administration in schizophrenia incorporating efficacy measures are indicated. As discussed 
above, it would also be useful if future studies stratified patient samples by antipsychotic 
response, as the effects of NAC may be more evident in patients in whom conventional 
treatment is ineffective. 
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